Christian D Sadik Ewan A Langan Victoria Grätz Detlef Zillikens Patrick Terheyden
10.3389/fimmu.2019.01934
Front Immunol
2019 Aug 14;10:1934.
lad-1 bullous pemphigoid checkpoint inhibitors melanoma nivolumab skin inflammation
CC BY
https://pubmed.ncbi.nlm.nih.gov/31474998/
Antineoplastic Agents, Immunological / adverse effects Autoantigens / genetics Autoantigens / immunology Immunoglobulin G / immunology Non-Fibrillar Collagens / genetics Non-Fibrillar Collagens / immunology Pemphigoid, Bullous / diagnosis Pemphigoid, Bullous / etiology
Antineoplastic Agents, Immunological / adverse effects Autoantigens / genetics Autoantigens / immunology Immunoglobulin G / immunology Non-Fibrillar Collagens / genetics Non-Fibrillar Collagens / immunology Pemphigoid, Bullous / diagnosis Pemphigoid, Bullous / etiology Case Reports Aged Antineoplastic Agents, Immunological / therapeutic use Autoantibodies / immunology Enzyme-Linked Immunosorbent Assay Female Fluorescent Antibody Technique Humans Immunoglobulin G / blood Immunosuppressive Agents / therapeutic use Melanoma / complications Melanoma / drug therapy Non-Fibrillar Collagens / antagonists & inhibitors Pemphigoid, Bullous / drug therapy Skin / immunology Skin / pathology Treatment Outcome Antineoplastic Agents, Immunological Autoantibodies Autoantigens Immunoglobulin G Immunosuppressive Agents Non-Fibrillar Collagens collagen type XVII
PMC6703093
31474998
Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid
2019